
The episode discusses the real-world utility and implications of Multi-Cancer Early Detection tests with expert insights from Dr. Margaret Tempero.
Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero , UCSF Cancer Early Detection and Interception , to discuss whether these tests are truly ready for clinical prime time. Claim CME for this episode at curbsiders.vcuhealth.org ! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction 01:57 Current Cancer Screening Programs 06:05 Emerging Blood-Based Cancer Tests 11:55 Test Characteristics and Limitations 18:05 Practical Considerations for Patients 25:33 Direct-to-Consumer Testing/Whole Body MRIs 36:46 Navigating Positive Test Results 45:10 Anxiety and Patient Education 47:08 Future Directions in Cancer Screening Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Margaret Tempero…
Hosts: Matthew Watto, Paul Williams
Guest: Margaret Tempero
Organizations: UCSF Cancer Early Detection and Interception, Grail, Global Bio Access Fund, Bristol Myers Squibb, Astra Zeneca
Explore listener stats, chart rankings, contacts and more on the The Curbsiders Internal Medicine Podcast podcast page.